Therefore, more information is needed to determine the mortality risk associated with B2As in patients with confirmed HF. Furthermore, it is not known whether factors such as the dose, duration ...

The addition of β-adrenergic antagonists to the treatment ... Adapted from McMurray JJV. Major beta blocker mortality trials in chronic heart failure: a critical review. Heart.

Beta-blockers antagonize beta-1 and beta-2 receptors which are the usual targets ... and systolic congestive heart failure. Other less common indications include anxiety, migraine headache ...